Uni-Bio developing platelet stimulator for use with chemotherapy

By Lisa Kerner

Charlotte, N.C., Sept. 20 - Uni-Bio Science Group Ltd. and an independent biotechnology institute in the People's Republic of China collaborated on a phase 3 clinical trial of Recombinant Human Interleukin 11 (rhIL-11), a platelet stimulator, for the treatment of chemotherapy induced thrombocytopenia.

Non-myelosuppressed patients received rhIL-11 daily subcutaneous dosing for 14 days with platelet count increased in a dose-dependent manner. After treatment was discontinued, platelet counts continued to increase for up to seven days and then returned toward baseline within 14 days.

Uni-Bio is a Hong Kong-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.